These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 2431697)

  • 1. Cyclo (Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine.
    Lee JM; DeLeon-Jones F; Fields JZ; Ritzmann RF
    Alcohol Drug Res; 1987; 7(1):1-10. PubMed ID: 2431697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclo(Leu-Gly) has opposite effects on D-2 dopamine receptors in different brain areas.
    Lee JM; Ritzmann RF; Fields JZ
    Peptides; 1984; 5(1):7-10. PubMed ID: 6231532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclo(Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine: agonist binding to D2 dopamine receptors correlates with stereotypic behavior.
    Lee JM; Fields JZ; Ritzmann RF
    Life Sci; 1983; 33 Suppl 1():405-8. PubMed ID: 6229678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide inhibition of morphine-induced dopaminergic supersensitivity.
    Ritzmann RF; Lee JM; Fields JZ
    Life Sci; 1982 Nov 15-22; 31(20-21):2287-90. PubMed ID: 6891737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of morphine-induced changes in striatal (3H)-spiroperidol binding and stereotype-behavior by cyclo(Leu-Gly).
    Ritzmann RF; Lee JM; Fields JZ
    Life Sci; 1982 May; 30(18):1573-80. PubMed ID: 7200563
    [No Abstract]   [Full Text] [Related]  

  • 6. Binding of [3H]spiroperidol to striatal membranes of rats treated chronically with morphine. Influence of Pro-Leu-Gly-NH2 and cyclo(Leu-Gly).
    Bhargava HN
    Neuropharmacology; 1983 Dec; 22(12A):1357-61. PubMed ID: 6141535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
    Bhargava HN
    NIDA Res Monogr; 1984 Mar; 49():320-6. PubMed ID: 6148693
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
    Bhargava HN
    Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and reversal of dopamine receptor supersensitivity by cyclo(leucyl-glycyl) (CLG): biphasic dose-response curves.
    Drucker GE; Ritzmann RF; Wichlinski LJ; Engh K; Gordon JH; Fields JZ
    Pharmacol Biochem Behav; 1994 Jan; 47(1):141-5. PubMed ID: 8115415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of calmodulin-dependent phosphorylation in chronic sulpiride-induced striatal dopamine receptor supersensitivity.
    Lau YS; Runice C; Dowd F
    J Pharmacol Exp Ther; 1984 Apr; 229(1):32-7. PubMed ID: 6323689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C; Fage D; Scatton B
    Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
    Schröder U; Schröder H; Augustin W; Sabel BA
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of melanotropin release inhibiting factor, its metabolites and analogs on [3H]spiroperidol and [3H]apomorphine binding sites.
    Bhargava HN
    Gen Pharmacol; 1983; 14(6):609-14. PubMed ID: 6141122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cyclo(leucyl-glycyl) on nigrostriatal dopaminergic supersensitivity--inhibition of apomorphine-induced climbing.
    Fields JZ; Lee JM; Gordon JH; Wichlinski LJ; Ritzmann RF
    Neuropeptides; 1990 Aug; 16(4):207-11. PubMed ID: 2274115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.